107 related articles for article (PubMed ID: 7520407)
21. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.
Engblom P; Rantanen V; Kulmala J; Grènman S
Anticancer Res; 1996; 16(4A):1743-7. PubMed ID: 8712694
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
24. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer.
Villman K; Blomqvist C; Larsson R; Nygren P
Anticancer Drugs; 2005 Jul; 16(6):609-15. PubMed ID: 15930887
[TBL] [Abstract][Full Text] [Related]
26. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
27. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
29. Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer.
Bazzett LB; Watkins CS; Gercel-Taylor C; Taylor DD
Gynecol Oncol; 1999 Aug; 74(2):181-7. PubMed ID: 10419729
[TBL] [Abstract][Full Text] [Related]
30. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
31. Further experience in testing the sensitivity of human ovarian carcinoma cells to interferon in an in vitro semisolid agar culture system: comparison of solid and ascitic forms of the tumor.
Epstein LB; Shen JT; Abele JS; Reese CC
Prog Clin Biol Res; 1980; 48():277-90. PubMed ID: 6163159
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
33. Radiation responsiveness of human lung cancer cell lines measured with a short term semiautomatic assay.
Xing T; Brattstrom D; Bergqvist M; Isaksson U; Wagenius G; Brodin O
Anticancer Res; 2001; 21(6A):3925-8. PubMed ID: 11911271
[TBL] [Abstract][Full Text] [Related]
34. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
35. [Chemosensitivity testing for human ovarian cancer on in vitro colony assay].
Inoue K
Gan No Rinsho; 1984 Jul; 30(9 Suppl):1146-51. PubMed ID: 6471421
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
Brader KR; Wolf JK; Hung MC; Yu D; Crispens MA; van Golen KL; Price JE
Clin Cancer Res; 1997 Nov; 3(11):2017-24. PubMed ID: 9815592
[TBL] [Abstract][Full Text] [Related]
37. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
38. The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.
Ng TY; Ngan HY; Cheng DK; Wong LC
Gynecol Oncol; 1999 Nov; 75(2):194-7. PubMed ID: 10525371
[TBL] [Abstract][Full Text] [Related]
39. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
40. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
